CatalYm
Manufacturing · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Am Klopferspitz 19, Planegg, Bavaria, 82...Phone Number
+49 89200066440Website
www.catalym.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About CatalYm
CatalYm is a biotechnology company focused on developing innovative immunotherapies to combat cancer by targeting GDF-15, a key mechanism of resistance to cancer therapies. The company aims to enhance immune cell activation and tumor infiltration, thereby reinstating effective responses to checkpoint inhibition. Led by a team of experienced drug developers, CatalYm is dedicated to treating solid tumors and cachexia. Their ongoing clinical trials, including combinations of Visugromab with other treatments, highlight their commitment to advancing cancer care.Explore more
CatalYm Org Chart
SR
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CatalYm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at CatalYm
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if CatalYm is spiking on competitors!
CatalYm, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on CatalYm recently announced quarterly report
Product Launch: Get notified when CatalYm launches new products
Check if CatalYm has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once CatalYm has new funding data
Click to see if CatalYm had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at CatalYm
Find 2 more new buyers
Company Profile Activity
Activity Insights
CatalYm is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CatalYm is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CatalYm.
CatalYm financials insights
Gather financial insights about CatalYm, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$59M
2022
Series C
$49M
2024
Series D
$150M
CatalYm Tech Stack
A closer look at the technologies used by CatalYm
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
CatalYm News & Media
CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025
MUNICH--(BUSINESS WIRE)--CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug conjugates (ADCs). The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in Chicago, IL, April 25-30, 2025. The poster will highlight the potential of targeting Growth Differentiation Factor 15 (GDF-15) to enhance the activitCatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. He takes the helm as CatalYm enters a new stage of corporate and clinical development, including the initiation of a broad Phase 2b program for its lead candidate, visugromab, in nonCatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature
MUNICH--(BUSINESS WIRE)--Clinical proof of concept for CatalYm's lead drug candidate visugromab for reversing resistance through GDF-15 neutralization were published in Nature
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CatalYm
Sign Up For FreeTo access detailed company insights
CatalYm is a biotechnology company focused on developing innovative immunotherapies to combat cancer by targeting GDF-15, a key mechanism of resistance to cancer therapies. The company aims to enhance immune cell activation and tumor infiltration, thereby reinstating effective responses to checkpoint inhibition. Led by a team of experienced drug de... Read More
